Condition: Relapsed/Refractory Acute Myeloid Leukemia (AML) · Sponsor: Nanjing Chia-tai Tianqing Pharmaceutical
NTQ2494 tablet, an anti-tumor molecular targeted drug, is an AXL kinase inhibitor. The objectives were to evaluate the safety and tolerability, PK characteristics and preliminary efficacy of NTQ2494 tablets in patients with advanced hematological malignancies.
This description comes directly from the study's public registry record.
Yu meng Zhou · 86-025-85109999 · yumeng_zhou@163.com
Always discuss trial participation with your own doctor first.
| Hematology Hospital of the Chinese Academy of Medical Sciences | Tianjin, Tianjin Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06049667